학술논문
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Document Type
Article
Author
Caffo, Orazio; Frantellizzi, Viviana; Tucci, Marcello; Galli, Luca; Monari, Fabio; Baldari, Sergio; Masini, Cristina; Bortolus, Roberto; Facchini, Gaetano; Alongi, Pierpaolo; Agostini, Stefania; Zichi, Clizia; Biasco, Elisa; Fanti, Stefano; Pignata, Salvatore; Filice, Angelina; Borsatti, Eugenio; Rossetti, Sabrina; Spada, Massimiliano; Cortesi, Enrico
Source
Subject
*CASTRATION-resistant prostate cancer
*PROSTATE cancer patients
*ABIRATERONE acetate
*ANDROGEN receptors
*MEDICAL records
*
*
*
*
Language
ISSN
1619-7070
Abstract
Purpose: To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the daily clinical practice. Materials: We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl2 immediately after progressing during an AA treatment line in everyday clinical practice. Results: We reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl2 as second- or third-line treatment. [223Ra]RaCl2 treatment was well-tolerated; there were only four cases of grade 3 anaemia, two cases of grade 3 leukopenia and one case of grade 3 neutropenia. The overall fracture rate is 2.1%; one fracture was recorded during the course of [223Ra]RaCl2 treatment, and one was recorded 1 month after its end. The fractures both occurred at metastatic sites. Median OS from [223Ra]RaCl2 start was more than 14 months regardless of the treatment line when [223Ra]RaCl2 was administered. Conclusion: The findings of this study show that the treatment with [223Ra]RaCl2 immediately after AA was active and safe with a very low risk of a fracture. Thus, the present observational report makes a valuable contribution to the current debate concerning the risks and benefits of including [223Ra]RaCl2 in the therapeutic algorithm. [ABSTRACT FROM AUTHOR]